FDA Approves New Therapy for Secondary Hyperparathyroidism, a Major Complication Associated With Chronic Kidney Disease
Posted on: Friday, 27 May 2005, 12:00 CDT
NEW YORK, May 27 /PRNewswire/ -- ADDITIONAL RESOURCES: Video, hard copy requests, contact information and more available at http://www.prnewswire.com/broadcast/21750/consumer.shtml
STORY SUMMARY:
According to the National Kidney Foundation, more than 20 million Americans -- that's one in nine adults -- have chronic kidney disease or CKD. Millions more are at risk, creating what the National Institutes Of Health is calling a 'growing epidemic.' A major complication associated with chronic kidney disease is a condition called secondary hyperparathyroidism or SHPT. For many patients, SHPT can detrimentally impact bones and other vital organs, including the heart, muscles and nerves. Until now, doctors have had limited treatment options to manage SHPT in earlier-stage CKD patients.
The FDA just approved Zemplar capsules, an oral activated vitamin D therapy that reduces parathyroid hormone levels in patients with SHPT. In clinical trials, 91 percent of patients taking the drug showed a reduction in parathyroid hormone levels -- compared to only 13 percent of placebo patients. The number of CKD cases in the U.S. has more than doubled in the past decade and is expected to grow. Doctors say early treatment is key to help delay the onset of end stage renal disease and the possibility of dialysis treatment and kidney transplantation.
VIDEO PROVIDED BY: Abbott Labs
Video: http://www.prnewswire.com/broadcast/21750/consumer.shtml
Abbott Labs
CONTACT: MultiVu Media Relations, +1-800-653-5313 Ext. 3
Web site: http://www.multivu.com/
Source: PRNewswire
Related Articles
- 8 Ounces a Day of POM Wonderful 100% Pomegranate Juice May Slow Progression of Carotid Intima-Media Thickness (CIMT) in Patients with Elevated Cardiovascular Disease Risk Factors, Study Finds
- US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
- Surveyed Neurologists in Both the United States and Europe Indicate That a Once-Daily Transdermal Formulation of Levodopa Would Earn a 30 Percent Patient Share in Parkinson's Disease
- Nursing Research Grants Available to Improve Treatment of Patients With Auto-Immune Diseases and Cancer
- Humate-P(R) Approved to Prevent Excessive Bleeding in Patients With Von Willebrand Disease Undergoing Surgery
- MultiVu Video Feed: Intensive Lipitor Therapy Cuts The Risk of Hospitalizations Due to Heart Failure in Patients With Coronary Heart Disease, New Analysis Shows
- Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease
- Positive Findings From Clinical Studies of QUADRAMET(R) in Prostate Cancer Patients With Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium
- Pfizer's Norvasc Demonstrates Significant Reductions in Major Cardiovascular Events in Patients With Coronary Artery Disease
- Actelion Ltd.: New Scientific Studies Show Higher Than Expected Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases (CTD)
 |
 |
User Comments (0)
RSS Feeds